Could a $10 arthritis pill tame rare blood cancers?
NCT ID NCT06541249
First seen Jan 09, 2026 · Last updated Apr 30, 2026 · Updated 15 times
Summary
This study tests low-dose methotrexate, a safe and inexpensive drug used for decades in arthritis, as a new treatment for three rare blood cancers: polycythemia vera, essential thrombocythemia, and myelofibrosis. Researchers want to see if adding this pill to current therapy can shrink the spleen, improve symptoms, and lower blood counts. The goal is to find an affordable option for patients who cannot access costly newer drugs.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POLYCYTHEMIA VERA (PV) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ruttenberg Treatment Center
RECRUITINGNew York, New York, 10029, United States
Conditions
Explore the condition pages connected to this study.